ATE142258T1 - Menschlicher gefässpermeabilitätsfaktor - Google Patents

Menschlicher gefässpermeabilitätsfaktor

Info

Publication number
ATE142258T1
ATE142258T1 AT89870181T AT89870181T ATE142258T1 AT E142258 T1 ATE142258 T1 AT E142258T1 AT 89870181 T AT89870181 T AT 89870181T AT 89870181 T AT89870181 T AT 89870181T AT E142258 T1 ATE142258 T1 AT E142258T1
Authority
AT
Austria
Prior art keywords
vascular permeability
human vascular
permeability factor
human
factor
Prior art date
Application number
AT89870181T
Other languages
English (en)
Inventor
Pamela Jean Keck
Joseph Feder
Daniel Thomas Connolly
Jitka Vera Olander
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE142258T1 publication Critical patent/ATE142258T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT89870181T 1988-11-21 1989-11-20 Menschlicher gefässpermeabilitätsfaktor ATE142258T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27406188A 1988-11-21 1988-11-21
US07/377,037 US5240848A (en) 1988-11-21 1989-07-10 Dna sequences encoding human vascular permeability factor having 189 amino acids

Publications (1)

Publication Number Publication Date
ATE142258T1 true ATE142258T1 (de) 1996-09-15

Family

ID=26956578

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89870181T ATE142258T1 (de) 1988-11-21 1989-11-20 Menschlicher gefässpermeabilitätsfaktor

Country Status (7)

Country Link
US (1) US5240848A (de)
EP (1) EP0370989B1 (de)
JP (2) JP2567114B2 (de)
AT (1) ATE142258T1 (de)
DE (1) DE68927088T2 (de)
ES (1) ES2031806T3 (de)
GR (1) GR3021708T3 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE152626T1 (de) * 1989-03-24 1997-05-15 Univ California Endothelialer zellwachsfaktor, isolierung und expression
US20030114374A1 (en) * 1989-05-12 2003-06-19 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US7300791B2 (en) * 1989-05-12 2007-11-27 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
DE69024261T2 (de) * 1989-05-24 1996-07-18 Merck & Co Inc Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
EP0506477B1 (de) * 1991-03-28 1999-06-23 Merck & Co. Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP3172841B2 (ja) * 1992-02-19 2001-06-04 株式会社日立製作所 薄膜トランジスタとその製造方法及び液晶表示装置
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
EP0751992B1 (de) * 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US7153827B1 (en) * 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7186688B1 (en) * 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
ATE343400T1 (de) 1996-09-24 2006-11-15 Merck & Co Inc Verbindungen zur hemmung der angiogenese durch gentherapie
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
US20030165467A1 (en) * 1997-01-21 2003-09-04 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
AU745409B2 (en) 1997-01-29 2002-03-21 Cornell Research Foundation Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
WO1998058053A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
US20030092002A1 (en) * 1997-09-17 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
SG117417A1 (en) 1998-02-06 2005-12-29 Collateral Therpeutics Inc Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
ATE405651T1 (de) 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
US7344880B2 (en) * 1998-04-24 2008-03-18 Genentech, Inc. Nucleic acid encoding PRO9912 polypeptides
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6352975B1 (en) * 1998-09-09 2002-03-05 Scios Inc. Methods of treating hypertension and compositions for use therein
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
EP1183357A2 (de) * 1999-05-20 2002-03-06 Scios Inc. Vaskuläre endothelzellen wachstumsfaktordimere
AU5023300A (en) 1999-05-20 2000-12-12 Scios Inc. Vascular endothelial growth factor variants
US7307153B2 (en) * 1999-12-23 2007-12-11 Genentech, Inc. Antibodies that bind PRO9912
US20030153015A1 (en) * 2000-01-20 2003-08-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2275549A1 (de) 2000-06-23 2011-01-19 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2004505619A (ja) * 2000-08-04 2004-02-26 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2002228841C1 (en) * 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
AU2002256172A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
AU2002252631A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
JP2004536579A (ja) * 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
EP2311960A3 (de) 2001-08-29 2011-06-01 Genentech, Inc. Bv8-Nukleinsäuren und Polypeptide mit mitogener Aktivität
KR101215701B1 (ko) * 2002-07-19 2012-12-26 베스 이스라엘 데코니스 메디칼 센터 자간전증 또는 자간의 진단 및 치료 방법
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US20060057694A1 (en) * 2003-01-29 2006-03-16 Thomas Kenneth A Jr Rat receptor tyrosine knase, kdr
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
US20050214280A1 (en) * 2004-03-02 2005-09-29 Ludwig Institute For Cancer Research Method for inhibiting tumor formation and growth
US8273383B2 (en) * 2004-05-04 2012-09-25 Children's Medical Center Corporation Methods and compositions for treatment of preeclampsia
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AR050608A1 (es) * 2004-08-19 2006-11-08 Alza Corp Aparato y metodo para administracion transdermica de factores de crecimiento endotelial vascular
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
EP2347765B1 (de) 2004-09-24 2014-01-22 Beth Israel Deaconess Medical Center Verfahren zur Diagnose und Behandlung von Schwangerschaftskomplikationen
DE602005023216D1 (de) * 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
ATE553122T1 (de) 2005-02-28 2012-04-15 Sangamo Biosciences Inc Antiangiogene methoden und zusammensetzungen
CN101277704A (zh) * 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
AU2006259408A1 (en) * 2005-06-17 2006-12-28 Genentech, Inc. Use of VEGF for wound healing
WO2007024752A2 (en) * 2005-08-26 2007-03-01 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
EP2310507A4 (de) 2008-07-08 2013-03-20 David Gladstone Inst Verfahren und zusammensetzungen zur angiogenesemodulierung
EP2569253A4 (de) 2010-05-14 2013-10-02 Beth Israel Hospital Extrakorporale vorrichtungen und verfahren zur behandlung von komplikationen während einer schwangerschaft
RS62672B1 (sr) 2015-04-03 2021-12-31 Univ Massachusetts Oligonukleotidna jedinjenja za tretman preeklampsije i drugih angiogenskih poremećaja
US20160319278A1 (en) 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
CA3033368A1 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
JP7406793B2 (ja) 2017-06-23 2023-12-28 ユニバーシティー オブ マサチューセッツ ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
WO2020033899A1 (en) 2018-08-10 2020-02-13 University Of Massachusetts Modified oligonucleotides targeting snps
US11279930B2 (en) 2018-08-23 2022-03-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
WO2021242883A1 (en) 2020-05-26 2021-12-02 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
CN117677699A (zh) 2021-06-23 2024-03-08 马萨诸塞大学 用于治疗先兆子痫和其他血管生成病症的优化抗flt1寡核苷酸化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5008196A (en) * 1987-08-21 1991-04-16 Monsanto Company Stimulation of endothelial cell growth
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5038003A (en) * 1990-05-14 1991-08-06 T & B Industries, Inc. Waterproof electrical splice enclosure with specialized housing to prevent the wires from being removed from the waterproof material within the housing

Also Published As

Publication number Publication date
DE68927088T2 (de) 1997-02-20
DE68927088D1 (de) 1996-10-10
EP0370989B1 (de) 1996-09-04
US5240848A (en) 1993-08-31
JP2783385B2 (ja) 1998-08-06
JPH02282398A (ja) 1990-11-19
GR3021708T3 (en) 1997-02-28
EP0370989A2 (de) 1990-05-30
JP2567114B2 (ja) 1996-12-25
ES2031806T1 (es) 1993-01-01
JPH0923887A (ja) 1997-01-28
EP0370989A3 (de) 1991-10-09
ES2031806T3 (es) 1997-01-01

Similar Documents

Publication Publication Date Title
ATE142258T1 (de) Menschlicher gefässpermeabilitätsfaktor
NO883270D0 (no) Dna-klon for human vevfaktorinhibitor.
IT8867010A0 (it) Protesi valvolare cardiaca
ATE140962T1 (de) Dns-klone von menschlichem thrombomodulin
DE68925366D1 (de) Konjugierte polypeptide und verfahren zur herstellung und verwendung
ATE71658T1 (de) Verfahren zur herstellung von humanlysozym.
DK627687D0 (da) Hirudinvariant
NO883834D0 (no) Fremgangsmaate for fremstilling av nye hiv-proteiner og peptider.
DK203087A (da) Fremgangsmaade til fremstilling af fusionsproteiner og anvendelse af det derved fremstillede fusionsprotein som vaccine
NO881502D0 (no) Rekombinante htlv-111 proteiner og anvendelse av disse.
NO891926D0 (no) Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater.
FI890055L (fi) Menetelmä kahdesta -aminohaposta koostuvan kopolymeerin valmistamiseksi sekä näin saatu kopolymeeri
CA2003360A1 (en) Human vascular permeability factor
BR1100729A (pt) Polipeptìdeo modificado
ATE92106T1 (de) Polypeptid und dessen herstellung.
NO881501D0 (no) Rekombinante htlv-111 proteiner og anvendelse av disse.
IT8767012A0 (it) Peptidi anoressizzanti e ipotensivi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time